Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
ToT for targeted therapies was shorter than progression-free survival in clinical trials. However, patients eligible for targeted therapy still had a survival improvement during the study period.
Authors
- Andrew Booth (ORCID: https://orcid.org/0000-0003-4808-3880)
- Ingrid Engebretsen (ORCID: https://orcid.org/0000-0001-9608-6731)
- Odd Terje Brustugun (ORCID: https://orcid.org/0000-0002-5153-8391)
- Åslaug Helland (ORCID: https://orcid.org/0000-0002-5520-0275)
- Lars Fjellbirkeland
- Christoffer Bugge (ORCID: https://orcid.org/0000-0002-0766-2870)
- Bjørn Henning Grønberg (ORCID: https://orcid.org/0000-0001-5744-1534)
- Francisco Oteiza (ORCID: https://orcid.org/0000-0002-3747-9786)
- Øyvind Husby
- Johanne Elise Nyen
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- Drammen Hospital (NO)
- Vestre Viken Hospital Trust (NO)
- St Olav's University Hospital (NO)
- 657 Oslo (NO)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.3389/fonc.2025.1506041
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Pfizer